FGEN - フィブロジェン (FibroGen Inc) フィブロジェン

 FGENのチャート


 FGENの企業情報

symbol FGEN
会社名 FibroGen Inc (フィブロジェン)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 フィブロジェン(FibroGen Inc.)はファースト・イン・クラス治療薬のパイプラインを発見・開発する科学ベースのバイオ医薬品企業である。同社は貧血、線維性疾患、および癌の治療のための革新的医薬品を発展させるために、線維症および低酸素誘導因子(HIF)生物学および臨床開発に焦点を当てる。同社の最先端製品候補Roxadustatは慢性腎臓病(CKD)における貧血治療の第III相臨床開発におけるHIFプロリルヒドロキシラーゼ活性の経口小分子阻害剤で、低リスク骨髄異形成症候群の貧血 シンドローム(MDS)にある貧血の第III相発症に進む。同社はパムレブラブを開発した。パムレブラブは、臓器の機能不全および機能不全に至りうる持続性および過剰瘢痕を特徴とする慢性線維症および増殖性障害における共通因子である結合組織成長因子(CTGF)の活性を阻害する独自の治療用抗体である。   フィブロジェンは、研究に基づいた、米国のバイオ医薬品会社。深刻な医療領域を治療する新型治療薬の発見、開発、商業化に焦点を当てる研究を行う。様々な治療分野を対象に、複数のプログラムを生成する。製品候補は、経口低分子阻害剤「roxadustat(FG-4592)」がある。  
本社所在地 409 Illinois Street San Francisco CA 94158 USA
代表者氏名 Thomas B. Neff トーマス・B・ネフ
代表者役職名 Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号 +1 415-978-1200
設立年月日 1993年
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 423人
url www.fibrogen.com
nasdaq_url https://www.nasdaq.com/symbol/fgen
adr_tso
EBITDA EBITDA(百万ドル) -117.55900
終値(lastsale) 52.4
時価総額(marketcap) 4419070264.8
時価総額 時価総額(百万ドル) 4449.43
売上高 売上高(百万ドル) 145.65700
企業価値(EV) 企業価値(EV)(百万ドル) 3891.987
当期純利益 当期純利益(百万ドル) -69.47500
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 FibroGen Inc revenues increased 27% to $75.9M. Net loss increased 4% to $64.8M. Revenues reflect License and milestone revenue increase from $0K to $14.3M Development and other revenue (includes increase of 3% to $61.6M. Higher net loss reflects Research and Development - increase of 14% to $94.8M (expense) Stock-based Compensation in R&D increase of 36% to $14.3M (expense).

 FGENのテクニカル分析


 FGENのニュース

   FGEN CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.  2021/04/14 18:58:00 Benzinga
RADNOR, Pa. , April 14, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Northern District of California against FibroGen, Inc. (NASDAQ: FGEN ) ("FibroGen") on behalf of those who purchased or acquired FibroGen securities and/or sold put options from November 8, 2019 through April 6, 2021 , inclusive (the "Class Period"). Investor Deadline Reminder: Investors who purchased or acquired FibroGen securities during the Class Period may, no later than June 11, 2021 , seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this litigation please contact Kessler Topaz Meltzer & Check, LLP: James Maro, Esq. (484) 270-1453 or Adrienne Bell, Esq. (484) 270-1435; toll free at (844) 887-9500; via e-mail at info@ktmc.com ; or click https://www.ktmc.com/fibrogen-class-action-lawsuit?utm_source=PR&utm_medium=Link&utm_campaign=fibrogen FibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease, and cancer.
   Fibrogen Slumps on Safety Data Inconsistencies  2021/04/07 15:02:30 Investing.com
https://www.investing.com/news/stock-market-news/fibrogen-slumps-on-safety-data-inconsistencies-2468228
   FibroGen Stock Is Trading Lower As CEO Admits Manipulated Safety Data For Roxadustat  2021/04/07 09:54:12 Benzinga
FibroGen Inc (NASDAQ: FGEN ) stock plummeted after hours on Tuesday after a murky disclosure for roxadustat , the company’s anemia treatment in chronic kidney disease patients. While preparing for an advisory committee meeting ahead of potential approval of roxadustat, FibroGen said it realized it submitted altered information to the FDA about the drug’s cardiovascular safety. The FDA has tentatively scheduled a Cardiovascular and Renal … Full story available on Benzinga.com
   First Gen picks 2 bidders for Philippines LNG project - Offshore Energy  2021/03/22 08:16:59 Offshore Energy
FGEN LNG, a unit of First Gen for its LNG import facility, has shortlisted two bidders to supply FSRU for the terminal in Batangas.
   Leerink Partners Stick to Their Buy Rating for FibroGen By Investing.com  2021/03/18 11:58:57 Investing.com
Leerink Partners Stick to Their Buy Rating for FibroGen
   The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed  2021/02/12 13:10:51 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 12) 4D Molecular Therapeutics Inc (NASDAQ: FDMT ) Adagene Inc (NASDAQ: ADAG ) (went public Tuesday) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) AnaptysBio Inc (NASDAQ: ANAB ) (received a double upgrade from JPMorgan) AngioDynamics, Inc. (NASDAQ: ANGO ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) argenx SE – ADR (NASDAQ: ARGX ) Atea Pharmaceuticals Inc (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Bausch Health Companies Inc (NYSE: BHC ) Bolt Biotherapeutics Inc (NASDAQ: BOLT ) C4 Therapeutics Inc (NASDAQ: CCCC ) Cara Therapeutics Inc (NASDAQ: CARA ) Celcuity Inc (NASDAQ: CELC ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN ) DermTech Inc (NASDAQ: DMTK ) ( announced award of contract for coverage of its skin cancer gene expression test) ESSA Pharma Inc (NASDAQ: EPIX ) (reacted to first-quarter results) Evogene Ltd (NASDAQ: EVGN ) FibroGen Inc (NASDAQ: FGEN ) G1 Therapeutics Inc (NASDAQ: GTHX ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) (moved on M&A speculation) Guardant Health Inc (NASDAQ: GH ) Guardion Health Sciences Inc (NASDAQ: GHSI ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunome Inc (NASDAQ: IMNM ) Infinity Pharmaceuticals Inc.
   Elizabeth Yeu, M.D. and K. Peony Yu, M.D. Appointed to STAAR Surgical Board of Directors  2021/01/26 15:45:00 Business Wire
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the appointments of Elizabeth Yeu, M.D., Partner, Virginia Eye Consultants, and K. Peony Yu, M.D., retired Chief Medical Officer, FibroGen Inc., to its Board of Directors, effective January 21, 2021. “The addition of Dr. Elizabeth Yeu and Dr. K. Peony Yu to our Board of Directors illustrates
   First Gen to construct LNG terminal in March – The Manila Times  2021/01/21 15:15:11 The Manila Times
Listed First Gen Corp. expects to begin building its interim offshore liquefied natural gas (LNG) terminal by March, a top official said on Thursday. In a virtual energy forum, First Gen Executive Vice President and Chief Commercial Officer Jonathan Russell told attendees “the project has moved past the planning stage and it’s now moving ahead.” […]
   Insider Selling: FibroGen, Inc. (NASDAQ:FGEN) Director Sells 5,999 Shares of Stock  2021/01/16 09:17:26 Watchlist News
FibroGen, Inc. (NASDAQ:FGEN) Director Kalevi Kurkijarvi sold 5,999 shares of the business’s stock in a transaction that occurred on Thursday, January 14th. The shares were sold at an average price of $40.04, for a total value of $240,199.96. Following the completion of the sale, the director now owns 39,099 shares of the company’s stock, valued […]
   Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis  2020/11/27 07:02:00 PR Newswire
TOKYO, Nov. 27, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved EVRENZO®…
   First Gen to construct LNG terminal in March – The Manila Times  2021/01/21 15:15:11 The Manila Times
Listed First Gen Corp. expects to begin building its interim offshore liquefied natural gas (LNG) terminal by March, a top official said on Thursday. In a virtual energy forum, First Gen Executive Vice President and Chief Commercial Officer Jonathan Russell told attendees “the project has moved past the planning stage and it’s now moving ahead.” […]
   Insider Selling: FibroGen, Inc. (NASDAQ:FGEN) Director Sells 5,999 Shares of Stock  2021/01/16 09:17:26 Watchlist News
FibroGen, Inc. (NASDAQ:FGEN) Director Kalevi Kurkijarvi sold 5,999 shares of the business’s stock in a transaction that occurred on Thursday, January 14th. The shares were sold at an average price of $40.04, for a total value of $240,199.96. Following the completion of the sale, the director now owns 39,099 shares of the company’s stock, valued […]
   Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis  2020/11/27 07:02:00 PR Newswire
TOKYO, Nov. 27, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, "FibroGen") today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved EVRENZO®…
   First Gen eyes small-scale LNG development - Offshore Energy  2020/11/05 09:18:55 Offshore Energy
FGEN LNG, a unit of First Gen Corporation, is looking into the potential small-scale LNG development in the First Philippine Industrial Park (FPIP).
   Cramer Gives His Opinion On Jumia Technologies, Nio, More  2020/11/03 08:31:00 Benzinga
On CNBC's "Mad Money Lightning Round," Jim Cramer said Jumia Technologies AG - ADR (NYSE: JMIA) is a good spec. He likes the idea. FibroGen …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 フィブロジェン FGEN FibroGen Inc)

 twitter  (公式ツイッターやCEOツイッターなど)